<DOC>
	<DOCNO>NCT00104715</DOCNO>
	<brief_summary>RATIONALE : Androgens cause growth prostate cancer cell . Drugs , goserelin , may stop adrenal gland make androgen . Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop divide . Giving hormone therapy together docetaxel may effective treatment prostate cancer . It yet know whether give hormone therapy together docetaxel effective hormone therapy alone treat prostate cancer . PURPOSE : This randomized phase III trial study hormone therapy docetaxel see well work compare hormone therapy alone treat patient metastatic prostate cancer .</brief_summary>
	<brief_title>Hormone Therapy Docetaxel Hormone Therapy Alone Treating Patients With Metastatic Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare 36-month overall survival patient metastatic prostate adenocarcinoma treat hormonal therapy docetaxel vs hormonal therapy alone . - Compare 24-month progression-free survival ( biological progression and/or clinical progression ) patient treat regimen . - Compare quality life patient treat regimen . - Compare cost regimens patient . - Compare tolerability regimens patient . - Compare toxicity profile regimens patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive hormonal therapy comprise 1 follow : goserelin alone OR goserelin antiandrogen therapy OR surgical castration . Hormonal therapy continue development hormone resistance . Within 2 month initiation hormonal therapy , patient receive docetaxel IV every 3 week 9 course absence disease progression unacceptable toxicity . - Arm II : Patients receive hormonal therapy arm I . Quality life assess . PROJECTED ACCRUAL : A total 378 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Androgen Antagonists</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate adenocarcinoma Metastatic disease Measurable evaluable disease No brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy At least 3 month Hematopoietic WBC ≥ 2,000/mm^3 Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ( 2.5 time normal hepatic metastasis present ) AST ALT ≤ 1.5 time ULN ( 2.5 time normal hepatic metastasis present ) Renal Creatinine ≤ 150 μmol/L Cardiovascular No symptomatic coronary disease No congenital cardiac insufficiency No New York Heart Association class III IV cardiovascular disease No severe cardiovascular disease Other No severe peripheral neuropathy No active infection No malignancy within past 5 year except basal cell skin cancer No familial , social , geographical , psychological situation would preclude study compliance followup No serious disease would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy metastatic prostate cancer Prior chemotherapy allow provided follow true : Chemotherapy complete &gt; 1 year ago Prostatespecific antigen level remain stable No development metastasis within 1 year completion chemotherapy Endocrine therapy Prior hormonal therapy within past 2 month allow metastatic prostate cancer Radiotherapy More 4 week since prior radiotherapy metastatic site Surgery No prior surgical castration Other No concurrent investigational drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>